What is Tavin you drug?

Tavin EM is a medicine used to treat HIV and hepatitis B.


Tavin EM should always be used in combination with other HIV medicines for better effect. These drugs are very helpful in stopping the HIV virus from entering AIDS.


Ingredients Tavin em

Active ingredients: Tenof and Emtricit tablets, 200mg / 300mg.


Specification: Box of 30 tablets.


Origin: Emcure India.

Designate Tavin em

Treatment of HIV-1 . infection

Tavin-EM, a combination of Tenofo is indicated for the treatment of HIV-1 infection in adults.


Drugs used for pre-exposure prophylaxis of HIV-1

Tavin Em is indicated in combination with safer sex practices in pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection in high-risk adults. Thuốc Tavin Em mua ở đâu

When considering Tavin EM for pre-exposure prophylaxis, the following factors may help identify high-risk individuals: condom-free sex with an HIV carrier.

Hepatitis B virus

Follow the combination regimen prescribed by the treating doctor.

Recommended dose for the treatment of HIV-1 infection in adults

The recommended dose in adults is one tablet taken before or after a meal.

Recommended Dose for Prep . Exposure Prophylaxis

The dose in adults without HIV-1 infection is one tablet before or after a meal.

Dosage adjustment for renal failure

No dose adjustment is required for HIV-1-infected patients with mild renal impairment (creatinine clearance 50–80 mL/min).

The safety and effectiveness of dosing interval adjustment recommendations in patients with moderate renal impairment (creatinine clearance 30–49 mL/min) have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients.

Tavin Em side effects

The most common side effects in people taking this medicine for HIV1 infection include nausea, headache, dizziness, trouble sleeping, rash, unusual dreams, diarrhea, fatigue, trouble sleeping, weight loss and stomach ache.

Leave a comment

Your email address will not be published. Required fields are marked *